SCHEMBL3579289

SCHEMBL3579289

O=C(OO)c1cnc2occ(-c3ccccc3)c2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAMKK2 Q96RR4 3/20 0.45
CAMKK1 Q8N5S9 1/20 0.45
NPC1 O15118 3/20 0.40
POLB P06746 2/20 0.40
CHEK2 O96017 2/20 0.39
MKNK1 Q9BUB5 2/20 0.39
AXL P30530 2/20 0.37
KDR P35968 2/20 0.37
CDC7 O00311 1/20 0.37
PLK4 O00444 1/20 0.37
CHEK1 O14757 1/20 0.37
AURKA O14965 1/20 0.37
MAPK13 O15264 1/20 0.37
PDPK1 O15530 1/20 0.37
DYRK3 O43781 1/20 0.37
ROCK2 O75116 1/20 0.37
RPS6KA5 O75582 1/20 0.37
PRKD3 O94806 1/20 0.37
PAK4 O96013 1/20 0.37
ABL1 P00519 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3490103 0.72 ALDH1A1 (0.39) CAMKK2NPC1POLBMAPK1GSK3B
SCHEMBL11620715 0.67 POLB (0.59) NPC1POLBGSK3BPIN1ALDH1A1
SCHEMBL1902296 0.66 ACVR1 (0.40) CAMKK2CAMKK1NPC1AXLKDR
SCHEMBL9869238 0.66 PLK4 (0.47) CAMKK2CAMKK1NPC1POLBKDR
SCHEMBL11709594 0.65 PDGFRB (0.56) CAMKK2AXLKDREGFRMAPK1
SCHEMBL12365259 0.65 GSK3B (0.61) CAMKK2NPC1POLBEGFRGSK3B
SCHEMBL11623160 0.64 PIN1 (0.55) NPC1POLBPIM1MAPK1GSK3B
SCHEMBL3492704 0.64 MAPK1 (0.41) POLBLCKMAPK1ALDH1A1KDM4E
SCHEMBL29281919 0.63 MGAM (0.67) NPC1KDRCSNK1G2CLK4ALDH1A1
SCHEMBL8722051 0.62 PDCD1 (0.60) NPC1POLBEGFRGSK3BKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7674907-B2 Furanopyridine derivatives and methods of use AMGEN INC. (US) 2010-03-09 US disclosed
US-20060046977-A1 Furanopyridine derivatives and methods of use AMGEN INC. 2006-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060046977-A1 Furanopyridine derivatives and methods of use LCK, NFATC1, MINK1 CAMKK2 297/4885CAMKK1 58/4885NPC1 4177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.